Natera to Release Third Quarter 2015 Results on November 12, 2015

Oct 30, 2015, 08:00 ET from Natera, Inc.

SAN CARLOS, Calif., Oct. 30, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2015 after the market close on November 12, 2015. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.

Event:   

Natera's Third Quarter 2015 Results Conference Call 


Date:          

Thursday, November 12, 2015 


Time:      

1:30 p.m. PT (4:30 p.m. ET) 


Live Dial-In:   

(866) 864-2549, Domestic 



(704) 908-0477, International


Webcast:   

investor.natera.com


A webcast replay will be available at investor.natera.com following the call.

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation software system. Tests include the Spectrum pre-implantation genetic test for embryo selection during IVF; the Anora miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon carrier screen to detect inherited mutations; and the Panorama non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Contacts
Natera, Inc.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
mbrophy@natera.com

 

SOURCE Natera, Inc.



RELATED LINKS

http://www.natera.com